BioNexus Gene Lab (BGLC) Competitors $5.34 -0.02 (-0.37%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$5.31 -0.03 (-0.56%) As of 08/15/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BGLC vs. KDLY, BMGL, CCM, MRAI, BRTX, MGRX, SSY, DHAC, ACON, and ATIPShould you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Kindly MD (KDLY), Basel Medical Group (BMGL), Concord Medical Services (CCM), Marpai (MRAI), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), Digital Health Acquisition (DHAC), Aclarion (ACON), and ATI Physical Therapy (ATIP). These companies are all part of the "healthcare" industry. BioNexus Gene Lab vs. Its Competitors Kindly MD Basel Medical Group Concord Medical Services Marpai Biorestorative Therapies Mangoceuticals SunLink Health Systems Digital Health Acquisition Aclarion ATI Physical Therapy Kindly MD (NASDAQ:KDLY) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Is KDLY or BGLC more profitable? Kindly MD has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -22.85%. Kindly MD's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.Company Net Margins Return on Equity Return on Assets Kindly MDN/A N/A N/A BioNexus Gene Lab -22.85%-24.18%-20.14% Do institutionals & insiders believe in KDLY or BGLC? 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 50.5% of Kindly MD shares are owned by company insiders. Comparatively, 0.7% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation and earnings, KDLY or BGLC? BioNexus Gene Lab has higher revenue and earnings than Kindly MD. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKindly MD$2.47M33.32-$4.64M-$0.77-17.75BioNexus Gene Lab$9.51M1.01-$1.60MN/AN/A Does the media refer more to KDLY or BGLC? In the previous week, BioNexus Gene Lab had 1 more articles in the media than Kindly MD. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 1 mentions for Kindly MD. Kindly MD's average media sentiment score of 1.10 beat BioNexus Gene Lab's score of 0.43 indicating that Kindly MD is being referred to more favorably in the media. Company Overall Sentiment Kindly MD Positive BioNexus Gene Lab Neutral SummaryKindly MD beats BioNexus Gene Lab on 6 of the 10 factors compared between the two stocks. Get BioNexus Gene Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGLC vs. The Competition Export to ExcelMetricBioNexus Gene LabMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.63M$7.55B$5.68B$9.81BDividend YieldN/A2.79%3.79%4.12%P/E RatioN/A74.9431.0825.11Price / Sales1.0130.43467.01193.48Price / CashN/A25.7937.4059.05Price / Book1.1517.309.096.18Net Income-$1.60M$243.10M$3.26B$265.11M7 Day Performance-4.13%3.01%7.36%4.21%1 Month Performance25.65%1.52%5.47%2.01%1 Year Performance28.37%18.72%30.61%23.75% BioNexus Gene Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGLCBioNexus Gene Lab0.1469 of 5 stars$5.34-0.4%N/A+18.7%$9.63M$9.51M0.0030Short Interest ↑KDLYKindly MDN/A$7.58+19.4%N/A+821.5%$45.65M$2.47M-9.84N/ANews CoveragePositive NewsGap UpBMGLBasel Medical GroupN/A$2.05-0.5%N/AN/A$38.02MN/A0.0036CCMConcord Medical Services0.4742 of 5 stars$5.05-5.4%N/A-30.4%$23.18M$52.60M0.00970Negative NewsShort Interest ↑MRAIMarpaiN/A$1.34-0.7%N/A+187.9%$22.33M$34.87M-0.51150News CoverageGap UpBRTXBiorestorative Therapies2.527 of 5 stars$1.49+0.7%$18.00+1,108.1%-7.9%$11.11M$400K-1.017Earnings ReportAnalyst RevisionMGRXMangoceuticals0.4854 of 5 stars$1.77+1.1%N/A-97.7%$9.05M$620K-0.383Positive NewsEarnings ReportAnalyst UpgradeShort Interest ↑SSYSunLink Health Systems2.3732 of 5 stars$1.02-8.9%N/A+34.8%$7.18M$31.09M7.291,376Short Interest ↓High Trading VolumeDHACDigital Health AcquisitionN/A$1.39+14.9%N/A-54.1%$5.01MN/A0.002,021Gap UpHigh Trading VolumeACONAclarion1.7866 of 5 stars$7.40+5.7%$11,758.50+158,798.6%-99.6%$4.08M$50K0.007Earnings ReportGap UpATIPATI Physical TherapyN/A$0.68flatN/A-88.8%$2.98M$741.86M-0.045,600 Related Companies and Tools Related Companies KDLY Alternatives BMGL Alternatives CCM Alternatives MRAI Alternatives BRTX Alternatives MGRX Alternatives SSY Alternatives DHAC Alternatives ACON Alternatives ATIP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BGLC) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNexus Gene Lab Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNexus Gene Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access